Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

RACCResearch Alliance Corp III

Nasdaq · CIK 0002118032
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts61

Identity from submissions API

NameResearch Alliance Corp III
CIK0002118032
TickersRACC
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN981918931
LEI—
Fiscal year end1231
State of incorporationE9 Cayman Islands
Phone(617) 778-2500
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
600 FIFTH AVENUE, 23RD FLOOR
NEW YORK
NY
10020
NY
Mailing address
600 FIFTH AVENUE, 23RD FLOOR
NEW YORK
NY
10020
NY

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

51 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128735 005-95731 261563834 34 11073
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-463814 005-95731 261562685 34 10173
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-052395 005-95731 261561123 34 11715
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005054 005-95731 261555122 34 15024
2026-11-16 10-Q 10-Q 0001193125-26-461340 001-43302 261554843 34 3895985 1 1
2026-11-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001011438-26-000689 005-95731 261552437 34 17265
2026-11-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-003436 333-298537 261524408 33 2703
2026-11-04 424B4 424B4 0001193125-26-447320 333-298537 261522558 33 7229953
2026-10-30 S-4/A S-4/A 0001193125-26-441817 333-298537 261508746 33 17592576 1 1
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000533 005-95731 261495003 34 171227
2026-10-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-114377 005-95731 261447353 34 1193431
2026-09-28 S-4/A S-4/A 0001193125-26-403078 333-298537 261411607 33 16775497 1 1
2026-09-16 425 425 0001193125-26-392963 001-43302 261383468 34 4102181
2026-09-11 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-004339 005-95731 261374279 34 12756
2026-09-11 425 425 0001193125-26-388359 001-43302 261372567 34 813421
2026-08-24 S-4 S-4 0001193125-26-363800 333-298537 261311669 33 17375214 1 1
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097423 005-95731 261284494 34 15201
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-352319 005-95731 261281954 34 123901
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-003434 005-95731 261275843 34 14894
2026-08-13 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-003433 005-95731 261270195 34 16200
2026-08-12 10-Q 10-Q 0001193125-26-346912 001-43302 261267801 34 3573270 1 1
2026-08-05 425 425 0001193125-26-335338 001-43302 261244382 34 183437
2026-08-03 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000405 005-95731 261233322 34 171175
2026-07-29 425 425 0001193125-26-321743 001-43302 261213641 34 406844
2026-07-28 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0002135648-26-000011 005-95731 261212050 34 26941
2026-07-28 425 425 0001193125-26-318558 001-43302 261207247 34 1178290
2026-07-27 425 425 0001193125-26-316960 001-43302 261202900 34 14591529
2026-07-27 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-26-316954 001-43302 261202896 34 15146201 1 1
2026-07-02 10-Q 10-Q 0001193125-26-294451 001-43302 261150860 34 2494444 1 1
2026-05-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001505 005-95731 261046448 34 38361
2026-05-29 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0002135648-26-000008 005-95731 261046311 34 24327
2026-05-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-026372 005-95731 261044623 34 23049
2026-05-28 8-K 8-K 8.01,9.01 0001193125-26-245567 001-43302 261038000 34 101577
2026-05-28 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000026 005-95731 261036188 34 15026
2026-05-28 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-245154 005-95731 261035336 34 772238
2026-05-21 4 xslF345X06/form4-05212026_080548.xml 0002135648-26-000003 5098
2026-05-21 4 xslF345X06/form4-05212026_080516.xml 0001817056-26-000003 5282
2026-05-21 8-K 8-K 1.01,3.02,5.02,5.03,8.01,9.01 0001193125-26-234382 001-43302 261008238 34 935810
2026-05-20 424B4 424B4 0001193125-26-232525 333-294549 261003856 33 1526555
2026-05-19 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001699 333-294549 261001262 33 1732
2026-05-19 3 xslF345X06/form3-05192026_080547.xml 0002135648-26-000002 5241
2026-05-19 3 xslF345X06/form3-05192026_080519.xml 0001817056-26-000002 10532
2026-05-19 3 xslF345X06/form3-05192026_080513.xml 0001692659-26-000005 9986
2026-05-19 3 xslF345X06/form3-05192026_080526.xml 0002124312-26-000002 8380
2026-05-19 3 xslF345X06/form3-05192026_080519.xml 0001383731-26-000008 10045
2026-05-19 3 xslF345X06/form3-05192026_080543.xml 0002133304-26-000003 8448
2026-05-18 CERT 8A_CERT_RACC_0002118032.pdf 0001354457-26-000474 001-43302 26992727 34 180256
2026-05-18 8-A12B 8-A12B 0001193125-26-228664 001-43302 26992047 34 12850
2026-05-13 S-1/A S-1/A 0001193125-26-220331 333-294549 26970654 33 4562955 1 1
2026-04-23 S-1/A S-1/A 0001193125-26-173973 333-294549 26889567 33 4612298 1 1
2026-03-24 S-1 S-1 0001193125-26-120705 333-294549 26784180 33 3931065 1 1

Latest XBRL company facts

One latest value per concept from companyfacts (61 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
ffd NetFeeAmt NetFeeAmt USD 31,475.5 2026-08-24 S-4 2026-08-24 0001193125-26-363800
ffd TtlFeeAmt TtlFeeAmt USD 31,475.5 2026-08-24 S-4 2026-08-24 0001193125-26-363800
ffd TtlOfferingAmt TtlOfferingAmt USD 227.92M 2026-08-24 S-4 2026-08-24 0001193125-26-363800
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-24 S-4 2026-08-24 0001193125-26-363800
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-08-24 S-4 2026-08-24 0001193125-26-363800
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 52,276 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 331,035 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap Assets Assets USD 78.90M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap AssetsCurrent Assets, Current USD 312,054 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 75.95M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 75.95M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap Cash Cash USD 183,405 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 183,405 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 183,405 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap CashFDICInsuredAmount Cash, FDIC Insured Amount USD 250,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price USD/shares 10 2026-11-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 128,033 2026-02-25 S-4 2026-08-24 0001193125-26-363800
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.18 2026-02-19 2026-02-25 S-4 2026-08-24 0001193125-26-363800
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.18 2026-02-19 2026-02-25 S-4 2026-08-24 0001193125-26-363800
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 1.23M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 383,311 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 8,697 2026-02-19 2026-02-25 S-4 2026-08-24 0001193125-26-363800
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 2,600 2026-02-19 2026-03-31 2026 Q1 10-Q 2026-07-02 0001193125-26-294451
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD 203,695 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 953,273 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap Liabilities Liabilities USD 6.85M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 78.90M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap LiabilitiesCurrent Liabilities, Current USD 2.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 76.23M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -75.00M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -1.05M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -1.96M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -734,126 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap NotesPayableCurrent Notes Payable, Current USD 300,000 2026-03-31 2026 Q1 10-Q 2026-07-02 0001193125-26-294451
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -1.23M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap OtherAssetsCurrent Other Assets, Current USD 2,600 2026-03-31 2026 Q1 10-Q 2026-07-02 0001193125-26-294451
us-gaap OtherIncome Other Income USD 238,468 2026-02-19 2026-06-30 S-4 2026-08-24 0001193125-26-363800
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.54M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PaymentsToInvestInDecommissioningFund Payments to Acquire Investments to be Held in Decommissioning Trust Fund USD 75.00M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 1.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 128,649 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap PrepaidExpenseNoncurrent Prepaid Expense, Noncurrent USD 75,046 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 75.00M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 25,000 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 2.75M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 300,000 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 300,000 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -3.90M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 0 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -3.90M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 25,000 2026-02-19 2026-03-31 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap TemporaryEquityIssuePeriodIncreaseOrDecrease Temporary Equity, Carrying Amount, Period Increase (Decrease) USD 4.72M 2026-02-19 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap TemporaryEquityValueExcludingAdditionalPaidInCapital Temporary Equity, Par Value USD 75.95M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-461340
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 189,076 2026-02-19 2026-02-25 S-4 2026-08-24 0001193125-26-363800
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 189,076 2026-02-19 2026-02-25 S-4 2026-08-24 0001193125-26-363800

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →